Breaking News Instant updates and real-time market news.

ORBC

Taken private

$11.51 /

+3.925 (+51.78%)

10:23
04/08/21
04/08
10:23
04/08/21
10:23

Orbcomm downgraded to Hold from Buy at Craig-Hallum

Craig-Hallum analyst Anthony Stoss downgraded Orbcomm to Hold from Buy with a $11.50 price target after the company announced an agreement to be acquired by GI Partners for $11.50 per share in cash.

  • 21

    Apr

OTHER BREAKING NEWS FROM THE FLY

Recommendations
Paramount price target lowered to $44 from $47 at Citi » 06:26
05/23/22
05/23
06:26
05/23/22
06:26
PARA

Paramount

$32.66 /

+0.43 (+1.33%)

Citi analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PARA Paramount
$32.66 /

+0.43 (+1.33%)

PARA Paramount
$32.66 /

+0.43 (+1.33%)

05/04/22 Deutsche Bank
Paramount price target lowered to $43 from $45 at Deutsche Bank
04/19/22 Rosenblatt
Paramount initiated with a Sell at Rosenblatt
04/14/22 Deutsche Bank
Paramount price target raised to $45 from $43 at Deutsche Bank
04/01/22 JPMorgan
Paramount reinstated with a Neutral at JPMorgan
PARA Paramount
$32.66 /

+0.43 (+1.33%)

PARA Paramount
$32.66 /

+0.43 (+1.33%)

PARA Paramount
$32.66 /

+0.43 (+1.33%)

PARA Paramount
$32.66 /

+0.43 (+1.33%)

Initiation
Horizon Therapeutics initiated with a Market Perform at SVB Leerink » 06:26
05/23/22
05/23
06:26
05/23/22
06:26
HZNP

Horizon Therapeutics

$90.33 /

+0.96 (+1.07%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$90.33 /

+0.96 (+1.07%)

HZNP Horizon Therapeutics
$90.33 /

+0.96 (+1.07%)

03/14/22 Oppenheimer
Horizon Therapeutics initiated with an Outperform at Oppenheimer
01/26/22 Piper Sandler
Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
01/18/22 JPMorgan
Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
12/08/21
Fly Intel: Top five analyst initiations
HZNP Horizon Therapeutics
$90.33 /

+0.96 (+1.07%)

HZNP Horizon Therapeutics
$90.33 /

+0.96 (+1.07%)

Upgrade
Consolidated Edison upgraded to Neutral from Sell at Guggenheim » 06:26
05/23/22
05/23
06:26
05/23/22
06:26
ED

Consolidated Edison

$95.81 /

+0.905 (+0.95%)

Guggenheim analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ED Consolidated Edison
$95.81 /

+0.905 (+0.95%)

ED Consolidated Edison
$95.81 /

+0.905 (+0.95%)

05/03/22 Wells Fargo
Wells Fargo downgrades Consolidated Edison to sell on 'tricky' NY rate case
05/02/22 Wells Fargo
Consolidated Edison downgraded to Underweight from Equal Weight at Wells Fargo
04/25/22 Credit Suisse
Consolidated Edison initiated with a Neutral at Credit Suisse
03/10/22 Mizuho
Consolidated Edison price target raised to $94 from $90 at Mizuho
ED Consolidated Edison
$95.81 /

+0.905 (+0.95%)

  • 16
    Jun
Recommendations
Dell Technologies price target lowered to $65 from $70 at Citi » 06:25
05/23/22
05/23
06:25
05/23/22
06:25
DELL

Dell Technologies

$40.05 /

-1 (-2.44%)

Citi analyst Jim Suva…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DELL Dell Technologies
$40.05 /

-1 (-2.44%)

DELL Dell Technologies
$40.05 /

-1 (-2.44%)

04/19/22 KGI Securities
Dell Technologies initiated with a Neutral at KGI Securities
04/01/22 Goldman Sachs
Dell Technologies downgraded to Neutral from Conviction Buy at Goldman Sachs
03/31/22 Barclays
Dell Technologies price target lowered to $53 from $54 at Barclays
03/31/22 Morgan Stanley
Dell Technologies downgraded to Equal Weight from Overweight at Morgan Stanley
DELL Dell Technologies
$40.05 /

-1 (-2.44%)

DELL Dell Technologies
$40.05 /

-1 (-2.44%)

DELL Dell Technologies
$40.05 /

-1 (-2.44%)

DELL Dell Technologies
$40.05 /

-1 (-2.44%)

Recommendations
Marvell price target lowered to $80 from $95 at UBS » 06:24
05/23/22
05/23
06:24
05/23/22
06:24
MRVL

Marvell

$54.13 /

-0.18 (-0.33%)

UBS analyst Timothy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$54.13 /

-0.18 (-0.33%)

MRVL Marvell
$54.13 /

-0.18 (-0.33%)

05/20/22 Oppenheimer
Marvell price target lowered to $90 from $110 at Oppenheimer
05/17/22 Piper Sandler
Piper moves to 'more positive stance' on semiconductor stocks
04/25/22 Raymond James
Marvell upgraded to Outperform from Market Perform at Raymond James
04/25/22 Raymond James
Marvell upgraded to Outperform from Market Perform at Raymond James
MRVL Marvell
$54.13 /

-0.18 (-0.33%)

MRVL Marvell
$54.13 /

-0.18 (-0.33%)

MRVL Marvell
$54.13 /

-0.18 (-0.33%)

Recommendations
Foot Locker price target raised to $32 from $30 » 06:24
05/23/22
05/23
06:24
05/23/22
06:24
FL

Foot Locker

$31.52 /

+1.22 (+4.03%)

Baird analyst Jonathan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FL Foot Locker
$31.52 /

+1.22 (+4.03%)

FL Foot Locker
$31.52 /

+1.22 (+4.03%)

05/16/22 Deutsche Bank
Foot Locker price target lowered to $30 from $32 at Deutsche Bank
05/16/22 OTR Global
Foot Locker downgraded to Mixed from Positive at OTR Global
03/28/22 Cowen
Cowen cuts Foot Locker to Market Perform, more cautious following March data
03/28/22 Cowen
Foot Locker downgraded to Market Perform from Outperform at Cowen
FL Foot Locker
$31.52 /

+1.22 (+4.03%)

FL Foot Locker
$31.52 /

+1.22 (+4.03%)

FL Foot Locker
$31.52 /

+1.22 (+4.03%)

FL Foot Locker
$31.52 /

+1.22 (+4.03%)

Initiation
AbbVie initiated with an Underperform at SVB Leerink » 06:23
05/23/22
05/23
06:23
05/23/22
06:23
ABBV

AbbVie

$151.04 /

-0.8 (-0.53%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

05/13/22 Piper Sandler
Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler
05/06/22 Daiwa
AbbVie downgraded to Neutral from Outperform at Daiwa
05/03/22 Morgan Stanley
Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
05/02/22 Morgan Stanley
AbbVie's recent weakness a buying opportunity, says Morgan Stanley
ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

Recommendations
Stealth Biotherapeutics price target lowered to $1.50 from $4 at H.C. Wainwright » 06:22
05/23/22
05/23
06:22
05/23/22
06:22
MITO

Stealth Biotherapeutics

/

+

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MITO Stealth Biotherapeutics
/

+

MITO Stealth Biotherapeutics
/

+

07/01/21 Maxim
Stealth Biotherapeutics initiated with a Buy at Maxim
07/01/21 Maxim
Stealth Biotherapeutics initiated with a Buy at Maxim
Recommendations
Zymeworks price target lowered to $40 from $44 at H.C. Wainwright » 06:21
05/23/22
05/23
06:21
05/23/22
06:21
ZYME

Zymeworks

$5.99 /

+0.155 (+2.66%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZYME Zymeworks
$5.99 /

+0.155 (+2.66%)

ZYME Zymeworks
$5.99 /

+0.155 (+2.66%)

05/09/22 Citi
Zymeworks should reject 'opportunistic' $10.50 per share offer, says Citi
05/05/22 Guggenheim
Zymeworks upgraded to Buy at Guggenheim amid low expectations
05/05/22 Guggenheim
Zymeworks upgraded to Buy from Neutral at Guggenheim
03/15/22 Evercore ISI
Zymeworks initiated with an Outperform at Evercore ISI
ZYME Zymeworks
$5.99 /

+0.155 (+2.66%)

  • 27
    Jan
ZYME Zymeworks
$5.99 /

+0.155 (+2.66%)

Recommendations
Atara Biotherapeutics price target lowered to $29 from $31 at H.C. Wainwright » 06:20
05/23/22
05/23
06:20
05/23/22
06:20
ATRA

Atara Biotherapeutics

$5.17 /

+0.015 (+0.29%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ATRA Atara Biotherapeutics
$5.17 /

+0.015 (+0.29%)

ATRA Atara Biotherapeutics
$5.17 /

+0.015 (+0.29%)

05/09/22 Citi
Citi downgrades Atara Biotherapeutics on lack of near-term drivers
05/09/22 Citi
Atara Biotherapeutics downgraded to Neutral from Buy at Citi
03/28/22 JPMorgan
Atara Biotherapeutics price target lowered to $22 from $27 at JPMorgan
03/08/22 Mizuho
Atara Biotherapeutics price target lowered to $39 from $41 at Mizuho
ATRA Atara Biotherapeutics
$5.17 /

+0.015 (+0.29%)

Recommendations
Snowflake price target lowered to $180 from $260 at UBS » 06:20
05/23/22
05/23
06:20
05/23/22
06:20
SNOW

Snowflake

$141.51 /

-5.36 (-3.65%)

UBS analyst Karl…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

05/20/22 Barclays
Snowflake price target lowered to $218 from $313 at Barclays
05/18/22 Mizuho
Snowflake price target lowered to $225 from $370 at Mizuho
05/10/22 Truist
Snowflake price target lowered to $300 from $350 at Truist
04/25/22 Wolfe Research
Snowflake initiated with an Outperform at Wolfe Research
SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

Initiation
Amgen initiated with a Market Perform at SVB Leerink » 06:20
05/23/22
05/23
06:20
05/23/22
06:20
AMGN

Amgen

/

+

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMGN Amgen
/

+

AMGN Amgen
/

+

05/10/22 Mizuho
Amgen price target raised to $208 from $202 at Mizuho
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
04/28/22 BMO Capital
Amgen price target lowered to $243 from $263 at BMO Capital
04/28/22 Piper Sandler
Amgen price target raised to $260 from $255 at Piper Sandler
AMGN Amgen
/

+

AMGN Amgen
/

+

AMGN Amgen
/

+

AMGN Amgen
/

+

Recommendations
Angion Biomedica price target lowered to $28 from $32 at H.C. Wainwright » 06:20
05/23/22
05/23
06:20
05/23/22
06:20
ANGN

Angion Biomedica

$1.29 /

+0.05 (+4.03%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ANGN Angion Biomedica
$1.29 /

+0.05 (+4.03%)

ANGN Angion Biomedica
$1.29 /

+0.05 (+4.03%)

04/18/22 H.C. Wainwright
Angion Biomedica price target lowered to $32 from $50 at H.C. Wainwright
12/10/21 Oppenheimer
Angion Biomedica price target lowered to $8 from $15 at Oppenheimer
11/09/21 H.C. Wainwright
Angion Biomedica price target lowered to $50 from $100 at H.C. Wainwright
10/27/21 Oppenheimer
Angion Biomedica price target lowered to $15 from $38 at Oppenheimer
ANGN Angion Biomedica
$1.29 /

+0.05 (+4.03%)

Recommendations
Spero Therapeutics price target lowered to $10 from $37 at H.C. Wainwright » 06:20
05/23/22
05/23
06:20
05/23/22
06:20
SPRO

Spero Therapeutics

$1.37 /

-0.065 (-4.53%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPRO Spero Therapeutics
$1.37 /

-0.065 (-4.53%)

SPRO Spero Therapeutics
$1.37 /

-0.065 (-4.53%)

05/20/22 Berenberg
Spero Therapeutics downgraded to Hold from Buy at Berenberg
05/17/22 Cantor Fitzgerald
Spero Therapeutics price target lowered to $5 from $27 at Cantor Fitzgerald
05/04/22 Cowen
Spero Therapeutics downgraded to Market Perform from Outperform at Cowen
05/03/22 Evercore ISI
Evercore downgrades Spero with $2 target after 'shocking update'
SPRO Spero Therapeutics
$1.37 /

-0.065 (-4.53%)

SPRO Spero Therapeutics
$1.37 /

-0.065 (-4.53%)

Recommendations
BioXcel Therapeutics price target lowered to $110 from $134 at H.C. Wainwright » 06:19
05/23/22
05/23
06:19
05/23/22
06:19
BTAI

BioXcel Therapeutics

$13.61 /

+0.355 (+2.68%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$13.61 /

+0.355 (+2.68%)

BTAI BioXcel Therapeutics
$13.61 /

+0.355 (+2.68%)

05/13/22 Canaccord
BioXcel Therapeutics price target lowered to $75 from $84 at Canaccord
05/10/22 Truist
BioXcel Therapeutics price target lowered to $71 from $125 at Truist
04/20/22 Canaccord
BioXcel Therapeutics shares remain significantly undervalued, says Canaccord
04/14/22 H.C. Wainwright
BioXcel Therapeutics price target raised to $134 from $130 at H.C. Wainwright
BTAI BioXcel Therapeutics
$13.61 /

+0.355 (+2.68%)

  • 23
    Jun
BTAI BioXcel Therapeutics
$13.61 /

+0.355 (+2.68%)

Recommendations
Xencor price target lowered to $42 from $66 at Piper Sandler » 06:18
05/23/22
05/23
06:18
05/23/22
06:18
XNCR

Xencor

$23.53 /

+0.52 (+2.26%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XNCR Xencor
$23.53 /

+0.52 (+2.26%)

XNCR Xencor
$23.53 /

+0.52 (+2.26%)

05/06/22 Piper Sandler
Xencor price target lowered to $66 from $71 at Piper Sandler
02/24/22 H.C. Wainwright
Xencor price target lowered to $55 from $61 at H.C. Wainwright
02/10/22 BMO Capital
Xencor initiated with an Outperform at BMO Capital
01/03/22 Piper Sandler
Xencor named a top pick for 2022 at Piper Sandler
XNCR Xencor
$23.53 /

+0.52 (+2.26%)

Recommendations
Sutro Biopharma price target lowered to $14 from $29 at Piper Sandler » 06:18
05/23/22
05/23
06:18
05/23/22
06:18
STRO

Sutro Biopharma

$4.66 /

+0.12 (+2.64%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
STRO Sutro Biopharma
$4.66 /

+0.12 (+2.64%)

STRO Sutro Biopharma
$4.66 /

+0.12 (+2.64%)

05/11/22 H.C. Wainwright
Sutro Biopharma price target lowered to $30 from $35 at H.C. Wainwright
05/10/22 Wedbush
Sutro Biopharma price target lowered to $20 from $30 at Wedbush
03/07/22 JMP Securities
Sutro Biopharma price target lowered to $20 from $28 at JMP Securities
01/06/22 Wedbush
Sutro Biopharma price target lowered to $30 from $37 at Wedbush
STRO Sutro Biopharma
$4.66 /

+0.12 (+2.64%)

STRO Sutro Biopharma
$4.66 /

+0.12 (+2.64%)

Recommendations
Omega Therapeutics price target lowered to $7 from $30 at Piper Sandler » 06:18
05/23/22
05/23
06:18
05/23/22
06:18
OMGA

Omega Therapeutics

$2.70 /

-0.085 (-3.05%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OMGA Omega Therapeutics
$2.70 /

-0.085 (-3.05%)

OMGA Omega Therapeutics
$2.70 /

-0.085 (-3.05%)

08/24/21
Fly Intel: Top five analyst initiations
08/24/21 Wedbush
Wedbush bullish on Omega Therapeutics, initiates with an Outperform
08/24/21 Jefferies
Omega Therapeutics initiated with a Buy at Jefferies
08/24/21 Wedbush
Omega Therapeutics initiated with an Outperform at Wedbush
OMGA Omega Therapeutics
$2.70 /

-0.085 (-3.05%)

  • 30
    Jul
OMGA Omega Therapeutics
$2.70 /

-0.085 (-3.05%)

OMGA Omega Therapeutics
$2.70 /

-0.085 (-3.05%)

Recommendations
NextCure price target lowered to $13 from $21 at Piper Sandler » 06:17
05/23/22
05/23
06:17
05/23/22
06:17
NXTC

NextCure

$3.80 /

+0.125 (+3.41%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NXTC NextCure
$3.80 /

+0.125 (+3.41%)

NXTC NextCure
$3.80 /

+0.125 (+3.41%)

03/01/22 Ladenburg
NextCure initiated with Buy, $16 price target at Ladenburg
03/01/22 Ladenburg
NextCure initiated with a Buy at Ladenburg
11/05/21 Piper Sandler
NextCure's Phase II NC318 study continuing weekly dosing, says Piper Sandler
08/08/21 Piper Sandler
NextCure price target lowered to $21 from $26 at Piper Sandler
Hot Stocks
JPMorgan sees 12.5%-13% CET1 ratio at 1Q24 » 06:17
05/23/22
05/23
06:17
05/23/22
06:17
JPM

JPMorgan

$117.34 /

-0.945 (-0.80%)

The company's ROTCE…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JPM JPMorgan
$117.34 /

-0.945 (-0.80%)

JPM JPMorgan
$117.34 /

-0.945 (-0.80%)

05/13/22 Jefferies
JPMorgan price target lowered to $125 from $141 at Jefferies
05/03/22 Oppenheimer
Oppenheimer upgrades JPMorgan to Outperform on recent share weakness
05/03/22 Oppenheimer
JPMorgan upgraded to Outperform from Perform at Oppenheimer
04/14/22 Argus
JPMorgan price target lowered to $155 from $177 at Argus
JPM JPMorgan
$117.34 /

-0.945 (-0.80%)

JPM JPMorgan
$117.34 /

-0.945 (-0.80%)

JPM JPMorgan
$117.34 /

-0.945 (-0.80%)

JPM JPMorgan
$117.34 /

-0.945 (-0.80%)

Recommendations
Seres Therapeutics price target lowered to $7 from $32 at Piper Sandler » 06:17
05/23/22
05/23
06:17
05/23/22
06:17
MCRB

Seres Therapeutics

$3.57 /

+0.15 (+4.39%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MCRB Seres Therapeutics
$3.57 /

+0.15 (+4.39%)

MCRB Seres Therapeutics
$3.57 /

+0.15 (+4.39%)

04/06/22 H.C. Wainwright
Seres study discontinuation does not impact valuation, says H.C. Wainwright
08/03/21 Oppenheimer
Seres Therapeutics price target lowered to $16 from $18 at Oppenheimer
07/23/21
Fly Intel: Top five analyst downgrades
07/23/21 Oppenheimer
Seres Therapeutics price target lowered to $18 from $36 at Oppenheimer
MCRB Seres Therapeutics
$3.57 /

+0.15 (+4.39%)

Recommendations
Kymera Therapeutics price target lowered to $43 from $91 at Piper Sandler » 06:17
05/23/22
05/23
06:17
05/23/22
06:17
KYMR

Kymera Therapeutics

$14.80 /

-0.085 (-0.57%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$14.80 /

-0.085 (-0.57%)

KYMR Kymera Therapeutics
$14.80 /

-0.085 (-0.57%)

05/04/22 B. Riley
Kymera Therapeutics price target lowered to $50 from $67 at B. Riley
04/28/22 Credit Suisse
Kymera Therapeutics initiated with an Outperform at Credit Suisse
03/10/22 JPMorgan
Kymera Therapeutics initiated with a Neutral at JPMorgan
02/10/22 Wells Fargo
Wells Fargo bullish on Kymera Therapeutics, initiates with an Overweight
KYMR Kymera Therapeutics
$14.80 /

-0.085 (-0.57%)

  • 01
    Jul
KYMR Kymera Therapeutics
$14.80 /

-0.085 (-0.57%)

Recommendations
Kronos Bio price target lowered to $13 from $30 at Piper Sandler » 06:17
05/23/22
05/23
06:17
05/23/22
06:17
KRON

Kronos Bio

$3.81 /

+0.255 (+7.17%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KRON Kronos Bio
$3.81 /

+0.255 (+7.17%)

KRON Kronos Bio
$3.81 /

+0.255 (+7.17%)

02/27/22 Piper Sandler
Kronos Bio price target lowered to $30 from $50 at Piper Sandler
10/19/21 Cowen
Kronos Bio assumed with an Outperform at Cowen
06/24/21 H.C. Wainwright
Kronos Bio initiated with a Buy at H.C. Wainwright
06/11/21 Piper Sandler
Kronos Bio transferred with Overweight, $50 target at Piper Sandler
KRON Kronos Bio
$3.81 /

+0.255 (+7.17%)

Recommendations
Jounce Therapeutics price target lowered to $9 from $17 at Piper Sandler » 06:17
05/23/22
05/23
06:17
05/23/22
06:17
JNCE

Jounce Therapeutics

$4.69 /

+0.16 (+3.53%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JNCE Jounce Therapeutics
$4.69 /

+0.16 (+3.53%)

JNCE Jounce Therapeutics
$4.69 /

+0.16 (+3.53%)

05/12/22 Roth Capital
Jounce Therapeutics recent pullback overdone, says Roth Capital
05/11/22 Baird
Jounce Therapeutics downgraded on JTX-8064 concerns at Baird
05/11/22 Baird
Jounce Therapeutics downgraded to Neutral from Outperform at Baird
05/06/22 Raymond James
Jounce Therapeutics upgraded to Strong Buy from Outperform at Raymond James
JNCE Jounce Therapeutics
$4.69 /

+0.16 (+3.53%)

JNCE Jounce Therapeutics
$4.69 /

+0.16 (+3.53%)

Recommendations
Infinity Pharmaceuticals price target lowered to $3 from $4 at Piper Sandler » 06:17
05/23/22
05/23
06:17
05/23/22
06:17
INFI

Infinity Pharmaceuticals

/

+

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
/

+

INFI Infinity Pharmaceuticals
/

+

03/31/22 Truist
Infinity Pharmaceuticals price target lowered to $4 from $12 at Truist
03/29/22 Piper Sandler
Infinity Pharmaceuticals price target lowered to $4 from $8 at Piper Sandler
01/24/22 B. Riley
Infinity Pharmaceuticals price target lowered to $5 from $7 at B. Riley
12/16/21 B. Riley
Infinity Pharmaceuticals price target raised to $7 from $4 at B. Riley
INFI Infinity Pharmaceuticals
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.